KR20130125994A - Compositions for the prevention and treatment of hyperlipidemia comprising extracts of clitoria ternatea as an active ingredient - Google Patents

Abstract

The present invention relates to a compound containing Clitoria ternatea extract as an active ingredient for preventing and treating hyperlipidemia, obesity, or fatty liver and, more specifically, the Clitoria ternatea extract according to the present invention which has no cytotoxicity and inhibits body weight gain due to a highocholesterol diet, liver and fat weight gain, and AST (aspartate aminotransferase) and ALT (Alanine aminoTransferase), and decreases the level of insulin, total cholesterol, LDL (low-density lipoprotein), triglyceride, and LDH (lactate dehydrogenase) and the production of IL-1β, IL-6, MCP-1, and TNF-a, and fat accumulation in the liver tissue, thereby being used effectively for developing the compound for preventing and treating hyperlipidemia, obesity, or fatty liver or a healthfood compound for preventing and improving hyperlipidemia, obesity, or fatty liver.

Description

Composition for the prevention and treatment of hyperlipidemia comprising extracts of Clitoria ternatea as an active ingredient

The present invention is a pea pea extract ( Clitoria ternatea ) relates to a composition for preventing and treating hyperlipidemia, obesity or fatty liver, and a composition for health food containing as an active ingredient.

Hyperlipidemia is a condition in which lipids such as cholesterol (triglyceride) or triglyceride are abnormally increased in plasma. Hyperlipidemia, especially hypercholesterolemia, leads to arterial thrombosis, which causes arteriosclerosis with thick lipids along the walls of blood vessels, which is a clinically important issue because it reduces blood flow and causes ischemic heart disease, angina pectoris, and myocardial infarction. . Lipoproteins that carry cholesterol in the blood are classified into two types, medium-size LDL and small-size HDL. Increased LDL cholesterol carried in LDL promotes atherosclerosis, and HDL cholesterol carried in HDL has a function of preventing atherosclerosis. As obesity increases, blood cholesterol and triglycerides increase, while HDL cholesterol decreases. In general, an inverse relationship exists between triglyceride levels and HDL cholesterol levels in lipoprotein metabolism. Therefore, the lowering of HDL cholesterol may be considered as a secondary change in hypertriglyceridemia in obese people. HDL cholesterol is lowered by obesity, diabetes, lack of exercise, smoking, and excessive intake of sugars. Therefore, to increase HDL cholesterol requires a modest diet, relieve obesity, proper exercise, quit smoking.

In general, dietary therapy, lifestyle therapy and drug therapy are used for the prevention and treatment of hyperlipidemia. The principle of dietary therapy is the basic calorie intake to maintain a normal weight, the total fat is 15 to 20% of the total calories, saturated, polyunsaturated, monounsaturated fatty acid composition of less than 6%, about 6%, respectively, It is preferable to make it 10% or less, and to make the calorie | sugar of a sugar and a protein 60-65%, 15-20%, respectively. In life therapy, regular exercise provides calorie balance in the body, helps to improve serum lipids such as decrease of LDL and increase of HDL cholesterol, and appropriate age and physical fitness, heart condition, preference, etc. To receive.

According to the type of hyperlipidemia, statins, which are cholesterol synthesis inhibitors, are mainly used, and the combination of fibric acid and nicotinic acid is used depending on the level of triglyceride. When taking these medications, blood lipids should be measured at intervals of two to three months for short-term treatment and every four to six months for long-term treatment. Detailed instructions are provided for those with other diseases and complications. Antihyperlipidemia drugs, like high blood pressure medications, are the ones that have to be taken continuously for a lifetime, and thus are a representative market that continues to grow. In the domestic market, the growth rate has been 30-40% in recent years. Experts point out that even if medications return to normal levels of cholesterol in the blood, they should continue to take the medication for continued management. If you stop taking medication because your blood cholesterol levels have returned to normal levels, your blood cholesterol levels may return or rise.

In addition, the statin-based drug is a representative drug that acts mainly to reduce LDL cholesterol as a cholesterol lowering agent. Statin drugs, which appeared in the 1990s, are considered the most effective drugs to lower cholesterol. Statin (HMG-CoA Reductase Inhibitor) -based drugs inhibit the conversion of HMG-CoA, a major step in cholesterol synthesis, to mevalonic acid, which reduces the amount of cholesterol in hepatocytes, resulting in an increase in LDL receptors on the surface of hepatocytes, resulting in LDL cholesterol in the blood. This decreases by 18-55%, triglycerides by 7-30%, and increases HDL (high-density lipoprotein) cholesterol by 5-15%. Statin-based drugs include atorvastatin, fluvastatin, lovastatin, lovastatin, paravastatin, simvastatin, rosuvastatin, and the like. The fibric acid and nicotinic acid act as a neutral fat lowering agent to reduce VLDL levels. Fibrate activates peroxisome proliferator activated receptor alpha, which promotes lipoprotein lipase activity, increases the breakdown of VLDL and LDL to lower blood triglyceride levels by 40% and increases HDL. Increases cholesterol by 10-20% and lowers LDL cholesterol by 5-20%. Fibric acid derivatives include bezafibrate, ciprofibrate, citopibrate, etofibrate, fenofibrate, gemfibrozil, micronised, fenofibrate ). In addition, nicotinic acid reduces the synthesis of VLDL, a precursor of LDL. Inhibit the secretion of VLDL in the liver, reduce triglycerides, and reducing the secretion of VLDL also reduces the conversion to LDL to reduce LDL cholesterol.

In recent years, the search for a substance that reduces cholesterol and triglycerides in blood from natural ingredients is actively conducted. The use of natural substances or herbal medicines has the advantage of having no toxicity and side effects, and the prevention and treatment at the same time.

Butterfly Pea ( Calitoria) ternatea ( English name: Flos Clitoria Ternateae) is a perennial plant that lives in tropical and temperate regions and has been reported to be used as a food dye or food ingredient. However, there has been no report on the efficacy of butterfly peas on hyperlipidemia.

On the other hand, as a technique for preventing and treating hyperlipidemia, Korean Publication No. 10-2009-0106274 discloses that cypress extracts are effective for hyperlipidemia or fatty liver, and Korean Publication No. 10-2010-0116919 Deodeok extract has been shown to be effective in obesity, hyperlipidemia or fatty liver, Republic of Korea Publication No. 10-2010-0122333 has a soybean leaf extract or a fraction thereof is significant for obesity, hyperlipidemia, arteriosclerosis, fatty liver, diabetes or metabolic syndrome It is disclosed that the effect, Republic of Korea Publication No. 10-2011-0095486 discloses that the polyphenol extract derived from Baumi situation mushroom is effective for hyperlipidemia, fatty liver or obesity. However, the efficacy of butterfly peas on hyperlipidemia is unknown.

Thus, the inventors of the present invention screening a new hyperlipidemia treatment material without side effects in natural products, the butterfly pea extract is not cytotoxic, inhibits weight gain by high cholesterol diet, inhibits the increase in liver and fat weight, AST inhibits aspartate aminotransferase (Alanine aminotransferase) and ALT (Alanine aminoTransferase) and reduces insulin levels, total cholesterol levels, low-density lipoprotein (LDL) cholesterol levels, triglyceride levels, and lactate dehydrogenase (LDH) By significantly reducing levels, significantly reducing the production of IL-1β, IL-6, MCP-1 and TNF-a, and significantly reducing fat accumulation in liver tissues, the butterfly pea extract is known for hyperlipidemia and obesity. Or the present invention has been completed by revealing that it can be usefully used as an active ingredient of a composition for preventing and treating fatty liver.

An object of the present invention is butterfly pea ( Clitoria) ternatea ) To provide a pharmaceutical composition for the prevention and treatment of hyperlipidemia, obesity or fatty liver containing the extract as an active ingredient, a composition for the prevention and improvement of hyperlipidemia, obesity or fatty liver.

In order to achieve the above object, the present invention is a butterfly pea ( Clitoria) ternatea ) provides a pharmaceutical composition for preventing and treating hyperlipidemia, obesity or fatty liver containing the extract as an active ingredient.

In addition, the present invention provides a composition for preventing and improving hyperlipidemia, obesity or fatty liver containing butterfly pea extract as an active ingredient.

Butterfly pea extract of the present invention ( Clitoria ternatea ) is non-cytotoxic, inhibits weight gain by high cholesterol diet, suppresses liver and fat weight gain, inhibits aspartate aminotransferase (AST) and alanine aminotransferase (ALT), insulin levels, Significantly lowered total cholesterol levels, low-density lipoprotein (LDL) cholesterol levels, triglyceride levels and lactate dehydrogenase (LDH) levels, and decreased IL-1β, IL-6, MCP-1 and Significantly decreases the production of TNF-a and significantly reduces the accumulation of fat in liver tissue, and therefore, in the development of pharmaceutical compositions for the prevention and treatment of hyperlipidemia, obesity or fatty liver, and for the development of health food compositions for the prevention and improvement of hyperlipidemia, obesity or fatty liver. Can be effectively used.

1 is a diagram showing the cell viability of butterfly pea extract:
Figure 2 is a diagram showing the weight change of hyperlipidemia disease model animals upon administration of butterfly pea extract:
Control: high cholesterol diet and saline (0.2 ml / day) group;
Atorvastin: group administered with Atorvastin (100 mg / kg), a high cholesterol diet and a drug for hyperlipidemia;
FCT 200: high cholesterol feed and butterfly pea extract 200 mg / 0.2ml / day administration group; And
FCT 400: High Cholesterol Feed and Butterfly Pea Extract 400 mg / 0.2ml / day.
Figure 3 is a diagram showing the change in the feed efficiency (feed efficiency rate) of hyperlipidemia disease model animals when the administration of butterfly pea extract:
Control: high cholesterol diet and saline (0.2 ml / day) group;
***: group administered with Atorvastin (100 mg / kg), a high cholesterol feed and hyperlipidemic drug;
FCT 200: high cholesterol feed and butterfly pea extract 200 mg / 0.2ml / day administration group; And
FCT 400: High Cholesterol Feed and Butterfly Pea Extract 400 mg / 0.2ml / day.
Figure 4 is a diagram showing the change in liver weight of hyperlipidemia disease model animals when the butterfly pea extract administration:
Control: high cholesterol diet and saline (0.2 ml / day) group;
Atorvastin: group administered with Atorvastin (100 mg / kg), a high cholesterol diet and a drug for hyperlipidemia;
FCT 200: high cholesterol feed and butterfly pea extract 200 mg / 0.2ml / day administration group; And
FCT 400: High Cholesterol Feed and Butterfly Pea Extract 400 mg / 0.2ml / day.
Figure 5 is a diagram showing the change in fat (fat) weight of hyperlipidemia disease model animals when the administration of butterfly pea extract:
Control: high cholesterol diet and saline (0.2 ml / day) group;
Atorvastin: group administered with Atorvastin (100 mg / kg), a high cholesterol diet and a drug for hyperlipidemia;
FCT 200: high cholesterol feed and butterfly pea extract 200 mg / 0.2ml / day administration group; And
FCT 400: High Cholesterol Feed and Butterfly Pea Extract 400 mg / 0.2ml / day.
Figure 6 is a diagram showing the change of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) of hyperlipidemia disease model animals upon administration of butterfly pea extract:
Control: high cholesterol diet and saline (0.2 ml / day) group;
Atorvastin: group administered with Atorvastin (100 mg / kg), a high cholesterol diet and a drug for hyperlipidemia;
FCT 200: high cholesterol feed and butterfly pea extract 200 mg / 0.2ml / day administration group; And
FCT 400: High Cholesterol Feed and Butterfly Pea Extract 400 mg / 0.2ml / day.
Figure 7 is a diagram showing the change in insulin (Insulin) levels of hyperlipidemia disease model animals when the administration of butterfly pea extract:
Control: high cholesterol diet and saline (0.2 ml / day) group;
Atorvastin: group administered with Atorvastin (100 mg / kg), a high cholesterol diet and a drug for hyperlipidemia;
FCT 200: high cholesterol feed and butterfly pea extract 200 mg / 0.2ml / day administration group; And
FCT 400: High Cholesterol Feed and Butterfly Pea Extract 400 mg / 0.2ml / day.
Figure 8 is a diagram showing the change in total cholesterol (total cholesterol) levels of hyperlipidemia disease model animals upon administration of butterfly pea extract:
Control: high cholesterol diet and saline (0.2 ml / day) group;
Atorvastin: group administered with Atorvastin (100 mg / kg), a high cholesterol diet and a drug for hyperlipidemia;
FCT 200: high cholesterol feed and butterfly pea extract 200 mg / 0.2ml / day administration group; And
FCT 400: High Cholesterol Feed and Butterfly Pea Extract 400 mg / 0.2ml / day.
Figure 9 is a diagram showing the change in LDL (Low-density lipoprotein) cholesterol levels of hyperlipidemia disease model animals when the administration of butterfly pea extract:
Control: high cholesterol diet and saline (0.2 ml / day) group;
Atorvastin: group administered with Atorvastin (100 mg / kg), a high cholesterol diet and a drug for hyperlipidemia;
FCT 200: high cholesterol feed and butterfly pea extract 200 mg / 0.2ml / day administration group; And
FCT 400: High Cholesterol Feed and Butterfly Pea Extract 400 mg / 0.2ml / day.
Figure 10 is a diagram showing the change in high-density lipoprotein (HDL) cholesterol level of hyperlipidemia disease model animals when the administration of butterfly pea extract:
Control: high cholesterol diet and saline (0.2 ml / day) group;
Atorvastin: group administered with Atorvastin (100 mg / kg), a high cholesterol diet and a drug for hyperlipidemia;
FCT 200: high cholesterol feed and butterfly pea extract 200 mg / 0.2ml / day administration group; And
FCT 400: High Cholesterol Feed and Butterfly Pea Extract 400 mg / 0.2ml / day.
Figure 11 is a diagram showing the change in triglyceride levels of hyperlipidemia disease model animals upon administration of butterfly pea extract:
Control: high cholesterol diet and saline (0.2 ml / day) group;
Atorvastin: group administered with Atorvastin (100 mg / kg), a high cholesterol diet and a drug for hyperlipidemia;
FCT 200: high cholesterol feed and butterfly pea extract 200 mg / 0.2ml / day administration group; And
FCT 400: High Cholesterol Feed and Butterfly Pea Extract 400 mg / 0.2ml / day.
12 is a diagram showing changes in lactate dehydrogenase (LDH) levels of hyperlipidemia disease model animals upon administration of butterfly pea extract:
Control: high cholesterol diet and saline (0.2 ml / day) group;
Atorvastin: group administered with Atorvastin (100 mg / kg), a high cholesterol diet and a drug for hyperlipidemia;
FCT 200: high cholesterol feed and butterfly pea extract 200 mg / 0.2ml / day administration group; And
FCT 400: High Cholesterol Feed and Butterfly Pea Extract 400 mg / 0.2ml / day.
Figure 13 is a diagram showing the change in IL-1β production of hyperlipidemia disease model animals upon administration of butterfly pea extract:
Control: high cholesterol diet and saline (0.2 ml / day) group;
Atorvastin: group administered with Atorvastin (100 mg / kg), a high cholesterol diet and a drug for hyperlipidemia;
FCT 200: high cholesterol feed and butterfly pea extract 200 mg / 0.2ml / day administration group; And
FCT 400: High Cholesterol Feed and Butterfly Pea Extract 400 mg / 0.2ml / day.
Figure 14 is a diagram showing the change in IL-6 production of hyperlipidemia disease model animals upon administration of butterfly pea extract:
Control: high cholesterol diet and saline (0.2 ml / day) group;
Atorvastin: group administered with Atorvastin (100 mg / kg), a high cholesterol diet and a drug for hyperlipidemia;
FCT 200: high cholesterol feed and butterfly pea extract 200 mg / 0.2ml / day administration group; And
FCT 400: High Cholesterol Feed and Butterfly Pea Extract 400 mg / 0.2ml / day.
Figure 15 is a diagram showing the change in MCP-1 production amount of hyperlipidemia disease model animals upon administration of butterfly pea extract:
Control: high cholesterol diet and saline (0.2 ml / day) group;
Atorvastin: group administered with Atorvastin (100 mg / kg), a high cholesterol diet and a drug for hyperlipidemia;
FCT 200: high cholesterol feed and butterfly pea extract 200 mg / 0.2ml / day administration group; And
FCT 400: High Cholesterol Feed and Butterfly Pea Extract 400 mg / 0.2ml / day.
Figure 16 is a diagram showing the change in TNF-a production of hyperlipidemia disease model animals upon administration of butterfly pea extract:
Control: high cholesterol diet and saline (0.2 ml / day) group;
Atorvastin: group administered with Atorvastin (100 mg / kg), a high cholesterol diet and a drug for hyperlipidemia;
FCT 200: high cholesterol feed and butterfly pea extract 200 mg / 0.2ml / day administration group; And
FCT 400: High Cholesterol Feed and Butterfly Pea Extract 400 mg / 0.2ml / day.
Figure 17 is a diagram showing the changes in liver tissue of hyperlipidemia disease model animals upon administration of butterfly pea extract:
Control: high cholesterol diet and saline (0.2 ml / day) group;
Atorvastin: group administered with Atorvastin (100 mg / kg), a high cholesterol diet and a drug for hyperlipidemia;
FCT 200: high cholesterol feed and butterfly pea extract 200 mg / 0.2ml / day administration group; And
FCT 400: High Cholesterol Feed and Butterfly Pea Extract 400 mg / 0.2ml / day.
Figure 18 is a diagram showing the change in the aortic arch of hyperlipidemia disease model animals upon administration of butterfly pea extract:
Control: high cholesterol diet and saline (0.2 ml / day) group;
Atorvastin: group administered with Atorvastin (100 mg / kg), a high cholesterol diet and a drug for hyperlipidemia;
FCT 200: high cholesterol feed and butterfly pea extract 200 mg / 0.2ml / day administration group; And
FCT 400: High Cholesterol Feed and Butterfly Pea Extract 400 mg / 0.2ml / day.

Hereinafter, the terminology of the present invention will be described in detail.

The term "hyperlipidemia" used in the present invention refers to a disease caused by a large amount of fat in the blood due to poor metabolism of triglycerides and cholesterol. More specifically, hyperlipidemia refers to high cholesterol hyperlipidemia with high incidence of lipid components such as triglycerides, LDL cholesterol, phospholipids and free fatty acids in the blood.

As used herein, the term "obesity" refers to an abnormally increased state of fat tissue, whether it is caused by environmental factors or obesity by genetic factors, and obesity according to the classification of body mass index (BMI is 30.0 or more). ) And overweight (BMI is 25-30).

As used herein, the term “fatty liver” refers to a condition in which fat is accumulated in liver cells due to fat metabolism disorder, which causes various diseases such as angina pectoris, myocardial infarction, stroke, arteriosclerosis, fatty liver and pancreatitis. .

As used herein, the term "prevention" means any action that inhibits hyperlipidemia, obesity or fatty liver by administration of the composition of the present invention.

As used herein, the terms “treatment” and “improvement” refer to all actions in which hyperlipidemia, obesity, or fatty liver improve or benefit altered by administration of a composition of the present invention.

Hereinafter, the present invention will be described in detail.

The present invention butterfly ( Clitoria) ternatea ) provides a pharmaceutical composition for preventing and treating hyperlipidemia, obesity or fatty liver containing the extract as an active ingredient.

The hyperlipidemia specifically includes, but is not limited to, hypercholesterolemia, hypertriglyceridemia, or low density lipoprotein cholesterol.

The butterfly pea extract is preferably prepared by a manufacturing method comprising the following steps, but not always limited thereto:

1) extracting by adding an extraction solvent to the butterfly pea;

2) filtering the extract of step 1);

3) Concentrating the filtered extract of step 2) under reduced pressure and drying to prepare an extract of butterfly pea.

In the above method, the butterfly pea of step 1) can be used without limitation, such as grown or commercially available.

In the above method, it is preferable to use water, an alcohol or a mixture thereof in the extraction solvent of the step 1). As the alcohol, C ₁ to C ₄ lower alcohol is preferably used, and as the lower alcohol, ethanol or methanol is preferably used. As the extraction method, it is preferable to use shaking extraction, Soxhlet extraction or reflux extraction, but it is not limited thereto. The extraction solvent is preferably extracted by adding 1 to 10 times the amount of dried butterfly pea, and more preferably by adding 2 to 3 times the extraction solvent. The extraction temperature is preferably 20 to 100 ° C, more preferably 20 to 40 ° C, and most preferably room temperature, but is not limited thereto. In addition, the extraction time is preferably 10 to 48 hours, more preferably 15 to 30 hours, most preferably 24 hours, but is not limited thereto. In addition, the extraction number is preferably 1 to 5 times, more preferably 3 to 4 repetitions, and most preferably 3 times, but is not limited thereto.

In the above method, the decompression concentration in step 3) preferably uses a vacuum decompression concentrator or a vacuum rotary evaporator, but is not limited thereto. In addition, the drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, but is not limited thereto.

In order to confirm the cytotoxicity of the butterfly pea extract, the present inventors divided raw 264.7 cells into 96 well plates at 10 ⁴ cells / well and incubated for 24 hours, and then the butterfly of the present invention. As a result of the treatment of pea extract, no significant decrease in cell viability was observed. Butterfly pea extract was confirmed that there is no cytotoxicity (see Fig. 1).

In addition, the present inventors in vivo ( In In vivo ) to determine the effect on hyperlipidemia, obesity or fatty liver, a control group ingesting a high cholesterol diet, a positive control group ingesting the high cholesterol diet and a hyperlipidemia atorvastatin (Atorvastin), and the high cholesterol diet and the present invention After separating the butterfly pea extract into the test group, after measuring weight change, dietary efficiency, liver and fat weight, liver amino acid ALT (aspartate aminotransferase) and AST (aspartate aminotransferase), insulin levels, blood factor and inflammatory cytokines As a result of measuring the amount of caine production, the butterfly pea extract of the present invention concentration-dependently inhibit the weight gain according to the high cholesterol diet (see Figs. 2 and 3), significantly reducing liver and fat weight compared to the control group (See FIGS. 4 and 5), ALT and AST levels (see FIG. 6), indicators of liver function, insulin levels (see FIG. 7), Significantly reduced cholesterol levels, LDL cholesterol levels, triglyceride levels, and LDH levels, which are indicators of liver damage (FIGS. 8-12), and serum inflammatory cytokines IL-1β, IL-6, MCP-1 and TNF- It was found to significantly reduce the production of a (see FIGS. 13-16).

In addition, the inventors of the present invention performed a hematoxylin and eosin (hematoxyline &eosin; H & E) after staining the liver after the end of the experiment in order to perform pathological examination of liver tissue, the butterfly pea extract administration group of the present invention It was confirmed that the fat accumulation in the tissue is significantly reduced (see FIG. 17).

Therefore, the butterfly pea extract of the present invention is not cytotoxic, inhibits weight gain by high cholesterol diet, inhibits increase in liver and fat weight, inhibits AST and ALT, insulin level, total cholesterol level, LDL Significantly reduces cholesterol levels, triglyceride levels and LDH levels, significantly reduces the production of IL-1β, IL-6, MCP-1 and TNF-a, and significantly reduces fat accumulation in liver tissue, It can be seen that it can be usefully used as an active ingredient in the prevention and treatment of hyperlipidemia, obesity or fatty liver.

The composition containing the butterfly pea extract of the present invention may further contain one or more active ingredients exhibiting the same or similar functions in addition to the above components.

The composition of the present invention may further comprise a pharmaceutically acceptable additive, wherein pharmaceutically acceptable additives include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose Starch glycolate, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, calcium stearate, , White sugar, dextrose, sorbitol and talc. The pharmaceutically acceptable additive according to the present invention is preferably included 0.1 to 90 parts by weight based on the composition, but is not limited thereto.

That is, the composition of the present invention can be administered in various formulations of oral and parenteral administration at the time of actual clinical administration. In the case of formulation, a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, . ≪ / RTI > Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and these solid preparations include at least one excipient such as starch, calcium carbonate, sucrose ( Sucrose), lactose (Lactose) or gelatin can be prepared by mixing. In addition to simple excipients, lubricants such as magnesium stearate talc may also be used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions and syrups, and various excipients such as wetting agents, sweetening agents, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used . Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. Examples of suppository bases include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like.

The composition of the present invention may be administered orally or parenterally in accordance with the intended method, and may be administered orally, parenterally or intraperitoneally, rectally, subcutaneously, intravenously, intramuscularly, . The dosage varies depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and disease severity.

The dosage of the composition of the present invention varies depending on the weight, age, sex, health condition, diet, time of administration, administration method, excretion rate and severity of the disease of the patient, the daily dosage is the amount of butterfly pea extract 0.0001 to 100 /, preferably 0.001 to 10 /, and may be administered 1 to 6 times a day.

The composition of the present invention can be used alone or in combination with methods for using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers for the prevention and treatment of hyperlipidemia, obesity or fatty liver.

In addition, the present invention provides a composition for preventing and improving hyperlipidemia, obesity or fatty liver containing butterfly pea extract as an active ingredient.

The hyperlipidemia specifically includes, but is not limited to, hypercholesterolemia, hypertriglyceridemia, or low density lipoprotein cholesterol.

The butterfly pea can be used without limitation, such as grown or commercially available.

The butterfly pea extract is preferably water, ethanol or a mixture thereof as a solvent, but is not limited thereto.

Butterfly pea extract of the present invention is not cytotoxic, inhibits weight gain by high cholesterol diet, inhibits increase of liver and fat weight, inhibits AST and ALT, insulin level, total cholesterol level, LDL cholesterol level Hyperlipidemia, as it significantly reduces triglyceride levels and LDH levels, significantly reduces production of IL-1β, IL-6, MCP-1 and TNF-a, and significantly reduces fat accumulation in liver tissue. It can be seen that it can be usefully used as an active ingredient of the health food composition for preventing and improving obesity or fatty liver.

The health food of the present invention may be added to the butterfly pea extract as it is, or used with other foods or food ingredients, and may be appropriately used according to conventional methods.

There is no particular limitation on the kind of the health food. Examples of foods to which the butterfly pea extract can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, ice cream, various soups, drinks, tea, Drinks, alcoholic beverages and vitamin complexes and the like, and includes all of the health food in the usual sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Such natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 ml of the composition of the present invention.

In addition to the above, the health food of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, , A carbonating agent used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not critical but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

Hereinafter, the present invention will be described in detail with reference to the following Examples, Experimental Examples and Production Examples.

However, the following Examples, Experimental Examples, and Production Examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following Examples, Experimental Examples, and Production Examples.

< Example 1 > Butterfly Pea Clitoria ternatea ) Preparation of extract

In order to prepare butterfly pea extract, 30 g of butterfly peas provided by the Cambodian Health Service were placed in a flask containing 0.5 L of 80% ethanol, filtered, and concentrated by a distillation apparatus. Then, the concentrate was completely dried using a freeze dryer to prepare 10.0 g of butterfly pea extract powder.

< Experimental Example  1> Confirmation of Cytotoxicity of Butterfly Pea Extract

In order to confirm the cytotoxicity of the butterfly pea extract prepared in Example 1, the raw 264.7 cells were dispensed into 96 well plates at 10 ⁴ cells / well and incubated for 24 hours. Thereafter, the butterfly pea extract prepared in Example 1 was treated at 25, 50, 100 and 200 ㎍ / ml, respectively, and incubated for 24 hours, followed by addition of 10 μl of WST solution. After 30 minutes of reaction in a CO ₂ incubator (37 ° C., 5% CO ₂ ), the change in absorbance at 450 nm was measured to express the cell viability of the control group as a percentage.

As a result, as shown in FIG. 1, the cell viability of the butterfly pea extract at 25, 50, 100 and 200 ug / ml was 109.9 ± 0.4, 100.2 ± 6.2, 108.2 ± 6.0 and 102.2 ± 2.2 (%), respectively. Viable pea extract was confirmed that there is no cytotoxicity (Fig. 1).

< Experimental Example  2> of Butterfly Pea Extract In vivo ( In vivo ) Antihyperlipidemic effect

<2-1> Preparation of Experimental Animal

The experimental animals were 6-week-old male ApoE knock-out (k / o) mice, which were hyperlipidemic disease model animals. It was imported from and used. The animals were fed with solid food (Table 2. AIN-76A diet Test Diet Co, USA) for 2 weeks, and then selected four healthy 10-week-old mice with constant weight changes, and then separated by four and 0.15% cholesterol (cholesterol). ), Western diet (21% fat) (Table 1. Research Diet, USA) and constant temperature (25 ± 2 ° C), constant humidity (50 ± 5%) and 12 hours with free water Experiments were carried out in SPF laboratories where the contrast was controlled by light intervals (light on 07:00-19:00). The contents and amounts of the general feed and the western diet were shown in the following [Table 2] and [Table 1], respectively.

Diets ingredient Concentration (g / kg) Casein, 80 Mesh 195 L-Cystine 3 Corn Starch 50 Maltodextrin 10 100 Sucrose 341 Cellulose 50 Milk Fat, Anhydrous 200 Corn oil 10 Mineral Mix S 10001 35 Calcium Carbonate 4 Vitamin Mix V10001 10 Choline Bitartrate 2 Cholesterol 1.5 Ethoxyquin 0.04

Dietary Feed Composition Quantity (g / kg) Casein 200 DL-Methionine 3 Corn Starch 150 Sucrose 500 Cellulose 50 Con oil 50 AIN-76 Mineral Mix 35 AIN-76A Vitamin Mix 10 Choline Bitartrate 2 Ethoxyquin 0.01

<2-2> Drug Administration

The ApoE k / o mice prepared in Experimental Example <2-1> were divided into four groups, and the drugs were administered. In addition, high cholesterol feed and saline were supplied daily, and atorvastatin and butterfly pea extracts were administered daily at a fixed time (11 AM):

Control group: high cholesterol feed and saline (0.2 ml / day) administration group prepared with the composition shown in Table 1;

Positive Control Group: Atorvastin (100 mg / kg) administration group, which is a high cholesterol feed and hyperlipidemic agent prepared with the composition shown in Table 1;

Butterfly pea extract 200 mg administration group: High cholesterol feed and butterfly pea extract 200 mg / 0.2 ml / day administration group prepared with the composition described in Table 1; And

400 mg / 0.2 ml / day administration group of high cholesterol feed and butterfly pea extract prepared with the composition described in [Table 1].

<2-3> Statistics Processing

The results obtained in all experiments were analyzed by ANOVA multi t-test (JAVA, Bonferroni Ver 1.1) to obtain p values. Each butterfly pea extract administration group was determined to be significant when p <0.05 compared with the control group.

<2-4> body weight and Dietary intake  Measure efficiency

After adapting the ApoE k / o mice to the basic diet (AIN-76A diet, Table 2) for 2 weeks, high cholesterol diet was divided into four groups as shown in Experimental Example <2-2> from 10 weeks of age [Table 1]. , Atorvastatin and butterfly pea extract administration were combined for 6 weeks. Dietary intake and body weight were measured every week at a certain time (5 pm), and the food efficiency ratio (Food efficiency ratio,%) was calculated using the following [Equation 2].

As a result, as shown in Table 3 and Figure 2, the change in weight every week for five weeks from the beginning of the administration of the butterfly pea extract, as a result of the significant control in the 11 weeks and 12 weeks positive control group (**: P <0.01, ***: P <0.001) In addition to the decrease was confirmed that the weight loss in the butterfly pea extract administration group (Fig. 2).

In addition, as shown in Figure 3, as a result of measuring the dietary efficiency, the control group was 8.33 ± 1.28 (FER,%), the positive control group was -2.25 ± 1.28 (FER,%), the butterfly pea extract 200 mg administration group Silver 5.19 ± 1.21 (FER,%), the butterfly pea extract 400 mg group was confirmed to be 4.95 ± 0.99 (FER,%) (Fig. 3). Therefore, it was confirmed that the butterfly pea extract inhibits the weight gain by high cholesterol diet in a concentration-dependent manner.

8 weeks 9 weeks 10 weeks Week 11 12 weeks Control group 23.0 ± 0.8 25.6 ± 0.4 26.6 ± 0.5 28.5 ± 0.3 29.3 ± 0.6 Positive control group 24.1 ± 0.7 24.8 ± 0.7 25.3 ± 0.8   25.6 ± 0.9 **    23.0 ± 1.3 *** Butterfly Pea Extract 200 mg 24.5 ± 1.2 25.0 ± 1.0 26.0 ± 0.7 27.3 ± 0.7 27.5 ± 1.4 Butterfly Pea Extract 400 mg 25.3 ± 1.6 27.1 ± 1.5 27.8 ± 1.7 28.5 ± 2.6 29.9 ± 2.4

<2-5> weight measurement

After completion of the experiment of Experimental Example <2-4>, the livers of ApoE knock-out (k / o) mice were extracted and weighed using a balance.

As a result, as shown in Figure 4, the weight of the liver of the control group was 1.68 ± 0.05 (g), the weight of the liver of the positive control group was 1.12 ± 0.07 (g), which was significant compared to the control group in the positive control group (***: P < 0.001), the liver weight of the butterfly pea extract 200 mg group was 1.26 ± 0.13 (g), and the liver weight of the butterfly pea extract 400 mg group was 1.35 ± 0.12 (g), which was significant (*: P). <0.05) a decrease was observed (FIG. 4).

<2-6> weight measurement of fat

After the experiment of Experimental Example <2-4>, the abdominal, epididymal, and inguinal adipose tissues of ApoE knock-out (k / o) mice were extracted by region. The total weight of the adipose tissue was then measured to calculate the weight of the adipose tissue per kg body weight.

As a result, as shown in FIG. 5, the control group showed 0.90 ± 0.05 (g) and the positive control group showed 0.29 ± 0.09 (g), which showed a significant decrease (***: P <0.001) in the positive control group. , 0.67 ± 0.08 (g) for butterfly pea extract 200 mg, 0.51 ± 0.06 (g) for butterfly pea extract 400 mg (*: P <0.05, ***: P <0.001) Fat weight loss was confirmed (FIG. 5).

<2-7> Measurement of liver function

After completion of the experiment of Experimental Example <2-4>, blood was taken from ApoE knock-out (k / o) mice, serum was isolated, and ALT (Alanine aminoTransferase) and AST (aspartate), which are indicator components of liver function measurement. aminotransferase) was measured.

As a result, as shown in FIG. 6, the ALT was 56.5 ± 18.8 (IU / L) in the control group, 23.4 ± 2.1 (IU / L) in the positive control group, and 36.2 ± 5.4 (IU / L) and 38.6 in the butterfly pea extract administration group, respectively. ± 6.0 (IU / L), AST was 139.1 ± 41.0 (IU / L) in the control group, 106.6 ± 22.8 (IU / L) in the positive control group and 87.5 ± 3.5 (IU / L in the butterfly pea extract administration group, respectively. And 127.9 ± 14.3 (IU / L), the butterfly pea extract of the present invention was found to significantly improve liver tissue damage caused by high cholesterol diet (Fig. 6).

<2-8> blood insulin ( insulin Biochemical analysis of

After completion of the experiment of Experimental Example <2-4>, the blood was collected by cardiac puncture from ApoE knock-out (k / o) mice, and centrifuged at 6,500 rpm for 20 minutes to separate serum, and then using ELISA kit. Insulin concentrations were measured.

Specifically, 10 μl of serum was dispensed into the wells, and 50 μl of biotin-conjugated antibody was added and mixed, followed by reaction at room temperature for 2 hours, using a washing buffer. Wash 4 times. 100 μl of streptavidin-HRP working solution was added thereto, followed by a dark reaction at room temperature for 30 minutes, and washing four times using a washing buffer. Then, 100 μl of stabilized chromogen was added and left in the dark for 30 minutes, and then treated with 100 μl of stop solution and absorbance was measured at 450 nm.

As a result, as shown in FIG. 7, the change in insulin was 1.65 ± 0.05 (ng / ml) in the control group and 0.69 ± 0.13 (ng / ml) in the positive control group, which was significantly higher than that of the control group in the positive control group, which is a hyperlipidemic agent. **: P <0.001) decreased, 1.53 ± 0.04 (ng / ㎖) for the butterfly pea extract 200 mg, 1.38 ± 0.10 (ng / ㎖) for the 400 mg butterfly pea extract group showed a decrease Significant (*: P <0.05) insulin reduction was observed as compared to the control group (FIG. 7).

<2-9> Blood factor measurement

After completion of the experiment of Experimental Example <2-4>, blood was collected through cardiac puncture in ApoE knock-out (k / o) mice, followed by total cholesterol (High Cholesterol), HDL (High-density lipoprotein), and LDL (Low-). The density lipoprotein (triglyceride) and LDH (lactate dehydrogenase) contents were measured by Biotoxtec (Ochang, Korea).

As a result, as shown in FIG. 8, the change in total cholesterol was 1371.3 ± 47.2 (mg / dL) in the control group and 994.7 ± 99.5 (mg / dL) in the positive control group. *: P <0.01) and the 200 mg butterfly pea extract group was 1309.3 ± 28.8 (mg / dl), and the 400 mg butterfly pea extract group was 1064.8 ± 131.1 (mg / dl), which showed a total cholesterol level. It was confirmed that the decrease (Fig. 8).

In addition, as shown in FIG. 9, the change in LDL cholesterol was 340.3 ± 11.0 (mg / dL) in the control group and 206.3 ± 48.0 (mg / dL) in the positive control group, which was significant (** in the positive control group). : P <0.01) and the 200 mg butterfly pea extract group showed 298.9 ± 6.2 (mg / dl), and the 400 mg butterfly pea extract group showed 200.4 ± 14.0 (mg / dl), which was significant (*). : P <0.05, ***: P <0.001) It was confirmed that showing the effect of reducing LDL cholesterol (Fig. 9).

In addition, as shown in Figure 10, the change in HDL cholesterol, the control group was 22.4 ± 1.5 (mg / ㎗), the positive control group appeared 16.5 ± 3.9 (mg / ㎗), the butterfly pea extract 200 mg administration group was 21.1 ± 1.1 (mg / ㎗), butterfly pea extract 400 mg group was found to be 16.5 ± 4.0 (mg / ㎗) did not significantly affect the change in HDL cholesterol (Fig. 10).

In addition, as shown in FIG. 11, the change in triglycerides was 170.0 ± 8.0 (mg / kV) in the control group and 80.0 ± 14.1 (mg / kL) in the positive control group, which was significant (***) in the positive control group. : P <0.001) showed a decrease of 200mg butterfly pea extract group and 111.7 ± 12.6 (mg / dl), and 400mg butterfly pea extract group showed 90.0 ± 27.7 (mg / dl). (**: P <0.01, *: P <0.05) was confirmed to decrease (Fig. 11).

In addition, as shown in FIG. 12, the change in serum LDH level was 1779.8 ± 214.0 (U / L) in the control group and 1134.0 ± 583.6 (U / L) in the positive control group. Pea extract 200 mg group showed 699.7 ± 152.8 (U / L) and butterfly pea extract 400 mg group showed 929.8 ± 211.3 (U / L), which showed significant LDH levels (*: P <0.05). It was confirmed that the reduction to) (Fig. 12).

<2-10> cytokine in serum ( cytokine ) Measure

In order to confirm the effect on the inflammatory cytokine (IL-1β, IL-6, MCP-1 and TNF-a) production of butterfly pea extract, ApoE knock-out after the end of the experiment of Experimental Example <2-4> (k / o) Mice were collected by cardiac puncture under anesthesia with ethyl ether, and then serum was separated by centrifugation at 6,500 rpm for 20 minutes. IL-1β, IL-6, MCP-1, TNF-a concentrations were measured as follows using a custom-made 4-plex cytokine Milliplex panel.

Specifically, 25 μl of serum was dispensed into the wells, and 25 μl of assay buffer, matrix buffer, and antibody-immobilized beads were added thereto, followed by mixing for 2 hours. Reaction at room temperature and washed twice using washing buffer. 25 μl of detection antibody was added thereto, followed by a dark reaction at room temperature for 1 hour, and an additional 25 μl of Streptavidin-Phycoerythrin was added at room temperature for 30 minutes, followed by washing buffer. (washing buffer) was washed twice. After washing, 150 μl of PBS was added and shaken for 5 minutes, followed by measurement using Luminex.

As a result, as shown in Figures 13 to 16, the butterfly pea extract of the present invention significantly reduced the production of inflammatory cytokines IL-1β, IL-6, MCP-1 and TNF-a in serum compared to the control group It was confirmed to make (Figs. 13 to 16).

< Experimental Example  3> Pathological examination of liver tissue and aortic arch

After completion of the experiment of Experimental Example <2-4>, the liver tissue and the aortic arch extracted for each experimental group were fixed in 10% neutral formalin for 48 hours, and the tissues were fixed by washing with flowing tap water for 12 hours to wash the fixed solution in the tissue. Complete removal For the dehydration of the tissue, the dehydration was carried out according to the conventional method in the order of increasing the concentration from 60% to 100% alcohol, and after the transparent process in xylene (xylene) to prepare a paraffin block. The prepared block is made into sections with a thickness of 34 ㎛ using a microtome, deparaffinized and hydrolyzed, followed by normal staining with hematoxylin and eosin (H & E) to observe and photograph on an optical microscope. Photographed.

As a result, as shown in Figure 17, after the end of the experiment, the liver was extracted and stained, and in the control group, a large number of white circular tissues, which are widespread fat vesicles caused by hepatic eatosis, were distributed, and thus a typical fatty liver (arrow) The lesions appeared, the cell nucleus was reduced, and the hepatic steatosis was suppressed in the positive control group and the butterfly pea extract administration group treated with Atorvastatin, which is a representative hyperlipidemia treatment agent, and the liver disappeared almost without fat. The state was confirmed (FIG. 17).

In addition, as shown in FIG. 18, after the end of the experiment, the aortic arch was extracted and H & E staining was performed. As a result, a necrotic core and cholesterol kraft were formed in the formation of a fat streak in which hyperlipidemia started. (cholesterol clefts), the lesion progresses to the intermediate stage, forming fibroproliferative lesions with a thick fibrous cap, showing calicification, leading to an intima thickness (arrow). It can be seen that the thickened, the positive control group was found to significantly reduce the thickness of the intima compared to the control group, the inner layer thickness of the butterfly pea extract administration group of the present invention was confirmed that the lesion progressed closer to the control (Fig. 18).

Preparation Example 1 Preparation of Pharmaceutical Formulation

<1-1> Preparation of powder

Butterfly pea extract of the present invention 2 g

Lactose 1 g

The above components were mixed and packed in airtight bags to prepare powders.

<1-2> Preparation of tablets

Butterfly pea extract of the present invention 100 mg

Corn starch 100 mg

Lactose 100 mg

Stearic Acid Magnesium 2 mg

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

&Lt; 1-3 > Preparation of capsules

Butterfly pea extract of the present invention 100 mg

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.

&Lt; 1-4 >

Butterfly pea extract of the present invention 1 g

Lactose 1.5 g

1 g of glycerin

Xylitol 0.5 g

After mixing the above components, they were prepared so as to be 4 g per one ring according to a conventional method.

<1-5> Preparation of granules

Butterfly Pea Extract 150 mg of the present invention

Soy extract 50 mg

Glucose 200 mg

Starch 600 mg

After mixing the above components, 100 mg of 30% ethanol was added and dried at 60 ° C. to form granules, and then filled into fabric.

< Manufacturing example  2> Manufacturing of food

<2-1> Production of flour food

0.5 to 5.0 parts by weight of butterfly pea extract of the present invention was added to flour, and bread, cake, cookies, crackers and noodles were prepared using the mixture.

<2-2> Production of soups and gravies

0.1-5.0 parts by weight of butterfly pea extract of the present invention was added to soups and gravy to prepare meat products for health promotion, soups and gravy of noodles.

<2-3> Preparation of ground beef

10 parts by weight of butterfly pea extract of the present invention was added to ground beef to prepare a ground beef for health promotion.

<2-4> Production of Dairy Products

5 to 10 parts by weight of butterfly pea extract of the present invention was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.

&Lt; 2-5 >

Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh.

Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer.

The butterfly pea extract of the present invention was concentrated under reduced pressure in a vacuum concentrator, and the dried product obtained by drying with a spray and a hot air dryer was pulverized with a particle size of 60 mesh to obtain a dry powder.

The grains, seeds and the butterfly pea extract of the present invention prepared in the above were formulated in the following ratio.

(30 parts by weight of brown rice, 15 parts by weight of yulmu, 20 parts by weight of barley)

Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)

Butterfly pea extract of the present invention (3 parts by weight),

(0.5 part by weight),

Rhubarb (0.5 parts by weight).

Preparation Example 3 Preparation of Beverage

<3-1> Production of health drinks

Instant sterilization by homogeneously mixing 5 g of butterfly pea extract of the present invention with subsidiary materials such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%) and water (75%). Then it was prepared by packaging in a small packaging container such as glass bottles, plastic bottles.

<3-2> Preparation of vegetable juice

Vegetable juice was prepared by adding 5 g of butterfly pea extract of the present invention to 1,000 ml of tomato or carrot juice.

<3-3> Production of fruit juice

1 g of butterfly pea extract of the present invention was added to 1,000 ml of apple or grape juice to prepare a fruit juice.

Claims (7)

Butterfly Pea ( Clitoria) ternatea ) Pharmaceutical composition for the prevention and treatment of hyperlipidemia, obesity or fatty liver containing the extract as an active ingredient.
According to claim 1, wherein the butterfly pea extract is water, C ₁ Pharmaceutical composition for the prevention and treatment of hyperlipidemia, obesity or fatty liver, characterized in that the extraction using a lower alcohol or a mixture of C ₄ ~ as a solvent.
The pharmaceutical composition for preventing and treating hyperlipidemia, obesity or fatty liver, characterized in that the lower alcohol is ethanol or methanol.
The pharmaceutical composition for preventing and treating hyperlipidemia, obesity or fatty liver, characterized in that the hyperlipidemia, hypertriglyceridemia, or low-density lipoprotein cholesterolemia.
Health food composition for the prevention and improvement of hyperlipidemia, obesity or fatty liver containing butterfly pea extract as an active ingredient.
The composition of claim 5, wherein the butterfly pea extract is extracted using water, ethanol or a mixture thereof as a solvent, wherein the composition is for preventing and improving hyperlipidemia, obesity or fatty liver.
According to claim 1, wherein the hyperlipidemia is hypercholesterolemia, hypertriglyceridemia, or low-density lipoprotein cholesterol, characterized in that the composition for health food for preventing and improving hyperlipidemia, obesity or fatty liver.

Images